Lung Cancer

Papers
(The TQCC of Lung Cancer is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-01-01 to 2025-01-01.)
ArticleCitations
Survival and soluble immune mediators of immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer136
Safety of G-CSF with concurrent chemo-radiotherapy in limited-stage small cell lung cancer - Secondary analysis of the randomised phase 3 CONVERT trial93
A whole-slide image (WSI)-based immunohistochemical feature prediction system improves the subtyping of lung cancer77
Tumor immune microenvironment of NSCLC with EGFR exon 20 insertions may predict efficacy of first-line ICI-combined regimen71
Role of 18F-FDG PET/CT in the postoperative follow-up in patients with stage I-III NSCLC: A retrospective single-institution study70
Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report69
Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer60
1000 Robotic-assisted lobectomies for primary lung cancer: 16 years single center experience57
Impact of genetic status on the survival outcomes of patients with clinical stage I non-small cell lung cancer with a radiological pure-solid appearance56
EpCAM-positive disseminated cancer cells in bone marrow impact on survival of early-stage NSCLC patients53
Imaging in pleural mesothelioma: A review of the 15th International Conference of the International Mesothelioma Interest Group52
Identification of inflamed-phenotype of small cell lung cancer leading to the efficacy of anti-PD-L1 antibody and chemotherapy50
Clinical and molecular characterization of long-term survivors with extensive-stage small cell lung cancer treated with first-line atezolizumab plus carboplatin and etoposide48
Real-world outcomes associated with afatinib use in patients with solid tumors harboring NRG1 gene fusions45
The Scottish Mesothelioma Network: impact of a national multidisciplinary team on overall survival in malignant pleural mesothelioma44
The impact of osimertinib’ line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance43
Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients43
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis42
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis40
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trial40
The relationship between body-mass index and overall survival in non-small cell lung cancer by sex, smoking status, and race: A pooled analysis of 20,937 International lung Cancer consortium (ILCCO) p39
Radiological precursor lesions of lung squamous cell carcinoma: Early progression patterns and divergent volume doubling time between hilar and peripheral zones37
Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon37
Clinical implementation of value based healthcare: Impact on outcomes for lung cancer patients36
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials36
Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung Cancer: A systematic review and meta-analysis35
Osimertinib is associated with reversible and dose-independent cancer therapy-related cardiac dysfunction35
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer35
149 Stereotactic radiosurgery (SRS) for the treatment of brain metastases: Outcomes for lung cancer patients in South Wales34
190 Decision Making for Thoracic Radiotherapy and Prophylactic Cranial Irradiation in ES-SCLC Post Chemoimmunotherapy34
66 Early Experiences of the Use of Combination Immunotherapy for the Treatment of Malignant Mesothelioma from 2022–2023 – Real-World Evidence of 1-Year Data from a Single UK Tertiary Cancer Centre34
84 National Real World Study of Adjuvant Osimertinib in Resected EGFR Mutated Lung Cancer33
2 The role of cellular pathology departments in the improvement of turnaround times for lung adenocarcinoma biomarker testing33
136 Supporting the wellbeing of oncodriven lung cancer patients online: a qualitative study33
216 Prolonged Localised Inflammatory Response following Bronchoscopic Thermal Vapour Ablation Therapy mimicking Lung Cancer32
207 Exploring the experiences of rural and coastal people with lung cancer and their informal carers' in accessing and engaging in treatment: A qualitative interview study32
133 Review of Advanced Lung cancer treatment in relation to the NLCA report32
205 An update on the VIGILANCE study: Developing Circulating and Imaging Biomarkers Towards Personalised Radiotherapy in Lung Cancer32
153 Lattice radiotherapy (LRT): Safely Dose Escalating Palliative Radiotherapy31
116 Health and Wellbeing days for Lung Cancer patients31
87 Overview of patients who complete two years of chemotherapy-immunotherapy for metastatic non-small cell lung cancer in Leicester30
64 Variability in patient pathways and experiences of care in peritoneal mesothelioma29
74 Is Age A Thing? Accessing Treatment for Pleural Mesothelioma29
181 Targeted Lung Health Check screening outcomes from invited ‘aged-in’ populations28
105 Implementation of a Lung Cancer Nurse Specialist 2WW Remote Outpatient Triage Clinic – Optimising Patient Access and Assessment28
219 Oesophageal EUS-guided Pericardiocentesis: A Therapeutic Conundrum in Patient with EGFR-positive Metastatic Lung Adenocarcinoma and Posterior Pericardial Tamponade28
48 Real world outcomes of a lung cancer genomic tumour advisory board: a single-centre experience in the United Kingdom28
213 Selpercatinib in RET Fusion Lung Adenocarcinoma27
90 Real world Time on Treatment (rwToT) of Pembrolizumab in Stage IV NSCLC—a single centre experience27
36 Summary of data for CT-guided percutaneous lung biopsy from West Yorkshire and Harrogate Cancer Alliance in 202127
198 Early experience with neoadjuvant immunochemotherapy and it's safety and efficacy27
196 Studying the Characteristics and Outcomes of People with Lung Cancer to Implement a Prehabilitation Service Pathway–A Retrospective Study27
123 Using Prescribing Data to Estimate the Number of ALKpositive Patients Currently Living in England27
108 Evaluation of a Lung Cancer Nurse led clinic for the routine follow up of uncomplicated post resection lung cancer patients26
178 Utility of PET-CT for nodule discrimination in the SUMMIT Study25
171 The impact of introducing a Targeted Lung Health Check on oncology services at Portsmouth Hospitals University NHS Trust25
164 Participant recollection of recent imaging is unreliable for determining eligibility for lung cancer screening25
111 Patient, professional and carer experiences of communicating a lung cancer diagnosis: A systematic review of qualitative evidence24
3 The Availability of Molecular Profiling Results at New Patient Review in NSCLC and the Impact on Patient Care24
206 SAFFRON: Savolitinib + Osimertinib vs Chemotherapy in EGFRm NSCLC with MET Overexpression/Amplification Post-Osimertinib24
143 Using ProKnow to explore the incidence of radiation pneumonitis in relation to GTV size in Stage III Non-Small Cell Lung Cancer (NSCLC) concurrent Chemoradiotherapy (cCRT) patients and its impact 24
Impact of first-line immunotherapy on survival and intracranial outcomes in a cohort of non-small cell lung cancer patients with brain metastases at diagnosis23
217 Atypical pseudoprogression in non-small cell lung cancer treated with pembrolizumab.23
Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis23
130 A review of patients diagnosed with non-small cell lung cancer, stage I-II disease and a performance status of 0–1 over the past 10 years23
Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial23
93 Evaluating real-world tepotinib-related toxicity data across five UK cancer units- A case-series23
Tumor response to EGFR/BRAF/MEK co-inhibition in a patient with EGFR mutated lung adenocarcinoma developing a BRAFV600 mutation as an acquired resistance mechanism22
The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy – a nationwide cohort study22
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients22
The Pandora’s box of novel technologies that may revolutionize lung cancer22
Surgical or medical strategy for locally-advanced, stage IIIA/B-N2 non-small cell lung cancer: Reproducibility of decision-making at a multidisciplinary tumor board21
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting f21
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trial21
NEPTUNE China cohort: First-line durvalumab plus tremelimumab in Chinese patients with metastatic non-small-cell lung cancer21
Is the onset of immune-related adverse events themselves a prognostic factor or a confounding factor?21
Analysis of rare fusions in NSCLC: Genomic architecture and clinical implications20
119 Estimating the health benefits of introducing ctDNA next generation sequencing to the diagnostic pathway for advanced lung cancer: A modelling study20
Contents20
Comparative effectiveness of second-line immune checkpoint inhibitor therapy versus chemotherapy for malignant pleural mesothelioma20
Deciphering the clinical features of heterogeneous stage III non-small cell lung cancer in Japanese real-world clinical practice: Expanded cohort of the SOLUTION study20
Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer20
Prognostic value of PET parameters in patients with pleomorphic lung cancer: Results from a single institution19
Adapting lung cancer diagnostics during the Covid-19 pandemic19
Correlation of 18F-FDG-PET/CT metabolic parameters with PD-L1 tumour proportion score (TPS) in resected non-small cell lung cancer (NSCLC)19
Gene-network analysis predicts clinical response to immunotherapy in patients affected by NSCLC19
The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)19
Durable response to serial tyrosine kinase inhibitors (TKIs) in an adolescent with metastatic TFG-ROS1 fusion positive Inflammatory Myofibroblastic Tumor (IMT)19
The effects of the COVID-19 pandemic on the lung cancer service at Northwick Park Hospital (NWPH)18
The safety and efficacy for the treatment of alectinib in a women with ALK-positive lung cancer delivered a healthy male neonate throughout Pregnancy: A case report18
Community Access To Chest CT (CATCH): experiences from a tertiary centre of the CATCH CT protocol for equivocal chest radiographs requested in primary care18
Pre-clinical modelling of ROS1+ non-small cell lung cancer18
Evaluation of telephone consultations for follow up lung cancer patients at Royal Papworth Hospital, undertaken instead of face-to-face consultations during the Covid-19 pandemic18
Preliminary review of the Lung One Stop Clinic in Greater Manchester18
Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations18
Impact of COVID-19 on mesothelioma clinical nurse specialists18
Where the nose is going to help the eye: Sniffing lung cancer18
Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies18
Regulation of immune microenvironment may enable MET-altered NSCLC patients to benefit from immune checkpoint inhibitors17
Prediction of next generation sequencing test failure in lung adenocarcinoma in a genomic laboratory hub setting17
Editorial Board17
An evaluation of a new local anaesthetic thoracoscopy service in Edinburgh17
Survival after surgery for clinical stage I non-small-cell lung cancer with interstitial pneumonia17
Preoperative PET-SUVmax and volume based PET parameters of the primary tumor fail to predict nodal upstaging in early-stage lung cancer17
FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-201017
The role of mediastinoscopy following EBUS17
Development and delivery of a second SABR service in Wales17
Increased proportion of patients diagnosed with lung cancer as a result of an acute hospital admission during the COVID-19 pandemic, and associated inequalities17
Real-world use of nivolumab plus ipilimumab in the management of diffuse pleural mesothelioma (DPM): experience from the county of Kent17
Radicality of lymphadenectomy in lung cancer resections by thoracotomy and video-assisted thoracoscopic approach: A prospective, multicentre and propensity-score adjusted study17
Efficacy and safety of durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer: a single institution experience at University Hospital of North Midlands (UHNM) in the United Kingdom17
Improving patient selection and referral for CT-guided lung biopsy at a tertiary referral centre17
Contents17
Contents17
Short communication: The activity of brigatinib in patients with disease progression after next generation anaplastic lymphoma tyrosine kinase inhibitors and an exploratory analysis of circulating tum17
Editorial Board17
The spectrum of MET exon 14 skipping alterations in a UK population17
Implementation of an antihypertensive deprescribing protocol in frail, stage IV lung cancer patients in clinical practice16
Dynamic monitoring of lung immune prognostic index (LIPI) in thoracic tumours treated with immune checkpoint inhibitors16
Radical chemoradiation for stage III NSCLC patients with N3 disease: futile exercise or a fruitful venture?16
Reducing inequalities in lung cancer: a new self-referral chest x-ray (SRCXR) service for symptoms that could be caused by lung cancer in Greater Manchester16
Does pleurodesis leave patients at risk from malignant ascites or contralateral pleural effusions: a prevalence study?16
A retrospective evaluation of risk factors for and incidence of Pneumocystis jirovecii pneumonia (PJP) in Patients treated with continuous hyperfractionated accelerated radiotherapy (CHART) in the Wes16
Mobocertinib in previously treated patients with EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): updated results from a phase 1/2 study16
Evaluating the need for, and provision of, a dietetic service in patients with early-stage lung cancer16
30-day mortality after SACT (systemic anti-cancer therapy) for lung cancer at the Northern Trust SACT clinic (2019-2021)16
Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma16
Surgical decompression of malignant spinal cord compression (MSCC) in lung cancer: the Manchester experience15
Randomized controlled clinical trial is needed for toxicity of IMRT VS 3D-CRT in PORT for LA-NSCLC15
Does consolidation radiotherapy to chest improve survival in extensive stage small cell lung cancer in the immunotherapy era? A retrospective study15
Embedding qualitative research in lung cancer trials: Thoracic Umbrella Radiotherapy Study in stage IV NSCLC: TOURIST15
The added value of screening for nutritional impact symptoms at the time of the new patient respiratory clinic for patients with suspected lung cancer15
A case study of an incidental finding of PJP on CBCT imaging in a stage III lung patient undergoing radical radiotherapy: a therapeutic radiographers experience15
Indwelling pleural catheter infections: a cautionary tale15
Incorporating circulating tumor DNA detection to radiographic assessment for treatment response in advanced EGFR-mutant lung cancer15
The impact of reminder invitations on participation in community-based lung cancer screening15
A retrospective study of pneumonectomy lung cancer patients spanning a 20 year period15
Non-metastatic small cell lung cancer: real-world data for patients receiving radical concurrent chemoradiotherapy15
Anlotinib plus docetaxel vs. docetaxel alone for advanced non-small-cell lung cancer patients who failed first-line treatment: A multicenter, randomized phase II trial15
Contents15
Impact of prehabilitation on pre-operative function, post-operative complications and length of stay in resectable lung cancers15
Direct to CT screening pilot for patients with COPD in a deprived area: longitudinal analysis of the pulmonary nodule cohort outcomes15
ETV6-NTRK3 translocation-associated low-grade mucinous bronchial adenocarcinoma: A novel bronchial salivary gland-type non-small cell lung cancer subtype14
The impact of virtual lung MDT meetings (MDTMs) in response to the COVID-19 pandemic14
Routine CT scans across the UK14
‘Do It For Yourself’: raising awareness of lung cancer symptoms to support early diagnosis14
Author index14
Use of DOACS for cancer-associated VTE in Great Western Hospital14
Use of systemic anti-cancer treatments in advanced stage non-small cell lung cancer during the SARS-CoV-2 pandemic in England and Wales: an analysis of the Rapid Cancer Registration Dataset14
Discordance between pre-operative and post-operative cell type after pleurectomy/decortication for malignant pleural mesothelioma: a possible detrimental effect of induction chemotherapy14
Microsimulation modeling of extended annual CT screening among lung cancer cases in the National Lung Screening Trial14
Assessment of the impact of SARS-CoV-2 PCR results amongst thoracic oncology patients14
Impact of risk-based low dose CT screening on different socio-economic groups14
Magnetic resonance imaging for prospective assessment of local recurrence of non-small cell lung cancer after stereotactic body radiation therapy14
Thymoma: a single centre, 10-year retrospective review13
Role of lung function in predicting risk of iatrogenic pneumothorax post CT-guided lung biopsy13
Integrated oncology and geriatrics care and outcomes in patients with lung cancer: results from Wythenshawe Hospital in Manchester, a tertiary referral centre13
Contents13
Real-world outcomes with nivolumab for pre-treated malignant mesothelioma in the UK13
A real-world description of pathogenic mutations and their genomic context in patients with lung adenocarcinoma in East London13
Bone protection and Pneumocystis jirovecii prophylaxis in thoracic oncology patients receiving systemic steroids for immunotherapy-related toxicity13
Toxicity rates of accelerated concurrent chemoradiation for NSCLC and access to durvalumab at a UK cancer centre13
Clinical score for colorectal cancer patients with lung-limited metastases undergoing surgical resection: Meta-Lung Score13
Pulmonary anatomy, pathology and treatment: What will be the artificial intelligence and deep-learning role on them?13
WHO histological classification and tumor size are predictors of the locally aggressive behavior of thymic epithelial tumors13
Efficacy, safety, and health-related quality of life from a global phase 3 study of tislelizumab as second- or third-line therapy for patients with locally advanced or metastatic non-small cell lung c13
Change in muscle mass and attenuation in patients receiving systemic anti-cancer therapy for advanced non-small cell lung cancer13
An integrated physiotherapy service for patients undergoing treatment for advanced thoracic cancers: an evaluation focusing on the patients’ perspectives13
Immune-related acute kidney injury in Australian non-small cell lung cancer patients: Real-world results13
Is MRI the superior test for investigating thymic pathologies in comparison to CT?13
Brief report on the efficacy of sotorasib in KRAS-Mutated NSCLC patients with brain metastases13
Stereotactic radiotherapy for early-stage (T1-2N0) small cell lung cancer: Where are we now and where are we going?13
Molecular testing in non-small cell lung cancer13
An invisible group of COVID-19 victims; impact on Dutch lung cancer care13
Patient survey to identify the outcome of the information given regarding lung cancer diagnosis and treatment12
Does lung cancer screening information support informed decision-making? A systematic environmental scan review12
Sarcopenia is not a useful prognostic biomarker in metastatic NSCLC patients treated with first-line pembrolizumab12
Analysis of investigation and management of patients with mesothelioma in the Mid Yorkshire Hospitals NHS Trust: a 5-year retrospective study12
Stereotactic ablative radiotherapy (SABR) for primary lung malignancy: a regional analysis of survival and recurrence outcomes amongst an elderly cohort12
Programmed death-ligand (PD-L1) expression and tissue heterogeneity in advanced non-small cell lung cancer (NSCLC)12
PDL-1 assessment – how does it affect lung cancer management? A service evaluation12
Radical radiotherapy in stage III NSCLC – why not chemoradiotherapy?12
Contents12
Review of the work-up for patients diagnosed with malignant pleural mesothelioma in Northern Ireland 2019–202012
Outcomes of surveillance imaging for non-small cell lung cancer patients treated with curative-intent: a single-centre retrospective longitudinal study12
Clinical frailty scoring in lung cancer patients referred for palliative radiotherapy12
Best practice in PD-L1 testing of non-small cell lung cancer in the UK: current problems and potential solutions12
Retrospective study to compare the dosimetric difference on treatment volume (PTV) and lung V20 in patients receiving lung stereotactic ablative radiotherapy (SABR) based on use of abdominal compressi11
Lung cancer patients over 70 years on systemic anti-cancer therapy: experience within a local centre11
Markers of efficacy in patients treated with immunotherapy for non-small cell lung cancer: a single cancer centre experience11
A reply to “Importance of designing sample size, subgroup analysis, and covariate presentation: Towards a better randomized controlled trial”11
Describing differences among populations of thoracic tumors patients under and over 80 years: Data analysis from the SLCG thoracic tumor registry11
Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study11
A novel intergenic (between REG3A and CTNNA2-AS1)-ALK fusion responds to alectinib in lung adenocarcinoma11
Two cases of non-small cell lung cancer patients with somatic or germline EGFR R776H mutation11
Dynamic cytokines signature predicts survival outcome from severe Immune-related hepatitis with PD-1/PD-L1 blockade in lung cancer11
Understanding patient experience: findings for Ireland and the UK and from the first Global Lung Cancer Coalition Patient Experience Survey11
Real world outcomes in patients with lung oligometastases treated with SABR – a single-centre experience11
Clinical relevance of circulating activin A and follistatin in small cell lung cancer11
A risk classification system predicting the cancer-specific survival for postoperative stage IB non-small-cell lung cancer patients without lymphovascular and visceral pleural invasion11
Usage of epidermal growth factor mutation testing and impact on treatment patterns in non-small cell lung cancer: An international observational study11
HLA-I levels correlate with survival outcomes in response to immune checkpoint inhibitors in non-small cell lung cancer11
Uncertain resection margins and patterns of recurrence following the surgical resection of non-small cell lung cancer11
How do we improve concurrent chemoradiotherapy rates in stage 3 NSCLC?11
Clinico-pathological features of MET exon 14 mutation positive NSCLC in the UK11
Molecular heterogeneity and co-altered genes in MET-amplified ALK-positive lung cancer: Implications for MET targeted therapy11
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial11
Outcomes of patients with advanced epithelial growth factor receptor mutant lung cancer treated with first-line osimertinib who would not have met the eligibility criteria for the FLAURA clinical tria11
Spatial microenvironment heterogeneity in therapy-naïve lung cancer: A concept with more attention needed11
Characterizing Lung-RADS category 4 lesions in a university lung cancer screening program10
OFCC1-ALK (Ointergenic: A20): A novel OFCC1 intergenic region-ALK fusion identified from a lung adenocarcinoma patient10
COVID-19 vaccination associated lung mass mimicking a primary lung cancer: a novel manifestation10
Prospective multicenter cohort study of durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis10
Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC)10
Editorial Board10
The first historical description of malignant mesotheliomas10
Explaining differences in the frequency of lung cancer detection between the National Lung Screening Trial and community-based screening in Manchester, UK10
Antimuscarinics and lung cancer survival: A Norwegian population-based cohort study10
Comparison of a ‘real-world’ inpatient talc slurry pleurodesis service with randomised controlled trial outcomes and suggested RAG rating criteria for quality assurance10
Contents10
Contents10
A prognostic score for patients with malignant pleural mesothelioma (MPM) receiving second-line immunotherapy or chemotherapy in the ETOP 9–15 PROMISE-meso phase III trial10
Acknowledgement to reviewers10
90-Day mortality following lung cancer surgery: contemporary outcomes from the English National Clinical Outcomes Audit10
Lung resection with underlying UIP: Russian roulette10
Editorial Board10
MET inhibitors for MET amplification—What’s the most appropriate detection method and cut-off value?10
Contents10
ctDNA analysis identifies clinically meaningful resistance mutations in EGFR mutated NSCLC on osimertinib: a case report9
Immunotherapy for mesothelioma: Moving beyond single immune check point inhibition9
Exploration on the first-line treatment of ERBB2-altered advanced non-small cell lung cancer: A multicenter retrospective study9
The reporting of pulmonary nodule results by letter in a lung cancer screening setting9
Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors9
Propensity score matched analysis for the role of surgery in stage Ⅲ small cell lung cancer based on the eighth edition of the TNM classification: a population study of the US SEER database and a Chin9
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC9
Drive the oncologists into exercise promotion in lung cancer9
Impact on quality of life from multi-modality treatment for lung cancer: a randomised controlled feasibility trial of surgery versus no surgery as part of multi-modality treatment in potentially resec9
Rapid intraoperative Ki-67 immunohistochemistry for lung cancer using non-contact alternating current electric field mixing9
Prognostic impact of inflammation in malignant pleural mesothelioma: A large-scale analysis of consecutive patients9
Thoracic NUT carcinoma: Common pathological features despite diversity of clinical presentations9
Continuing immune checkpoint inhibitors after progression: Real-world patterns of care and outcomes in second-line treatment for extensive-stage small-cell lung cancer9
Squamous cell carcinoma associated with acquired von Willebrand disease due to immune checkpoint inhibitor treatment9
A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer9
Immune checkpoint inhibitor induced thyroid dysfunction is a frequent event post-treatment in NSCLC9
The effect of the introduction of the national lung cancer screening program on short-term mortality in Korea9
HALT: targeted therapy with or without dose-intensified radiotherapy in oligo-progressive disease in oncogene addicted lung tumours9
Evaluating tumour budding could improve the new grading system for lung adenocarcinoma9
A potential treatment option for transformed small-cell lung cancer on PD-L1 inhibitor-based combination therapy improved survival9
Proliferative ability of circulating tumor cells is a prognostic factor in Early-Stage lung adenocarcinoma9
IL-9 stimulates an anti-tumor immune response and facilitates immune checkpoint blockade in the CMT167 mouse model9
1.2670409679413